Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12345678910111213...8687»
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene
    Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2081;    
    For the safety outcomes, mild immune-related AEs such as rash, pruritus,hypothyroidism, pneumonitis were experienced and none ?3irAE occurred. Conclusions : This study demonstrated that tislelizumab combined with platinum-based chemotherapy plus bone-targeted agents is a promising option in the first line therapy for advanced NSCLC patients with bone metastasis and baseline levels of NLR and PLR were important and associated with PFS outcomes of immunotherapy.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Journal:  Romosozumab Followed by Denosumab Versus Denosumab Only: A Post Hoc Analysis of FRAME and FRAME Extension. (Pubmed Central) -  Jul 23, 2024   
    Similar BMD and fracture outcomes were observed with PSW-MI and PSM sensitivity analyses. The sequence of Romo/DMAb resulted in greater BMD gains and higher probability of achieving T-scores > -2.5, significantly reduced new vertebral fracture incidence, and numerically lowered the incidence (not significant) of clinical, nonvertebral, and hip fractures versus DMAb only through 24
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Research progress on perioperative management of tooth extraction in denosumab-treated patients (Pubmed Central) -  Jul 22, 2024   
    However, the perioperative management strategies for DRONJ differ from those for bisphosphonate-related osteonecrosis of the jaw. This article summarizes the perioperative management strategies for high-risk DRONJ patients from aspects such as oral hygiene care, antibiotic use, drug discontinuation during the perioperative period, and surgical strategy selection, aiming to provide guidance for oral surgeons in managing tooth extraction in denosumab-treated patients.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis. (Pubmed Central) -  Jul 22, 2024   
    Multiple studies suggest that denosumab is both effective and safe, exhibiting higher adherence rates and greater patient satisfaction. In this narrative review, we highlighted the effects of denosumab in men with osteoporosis, subsequent changes in bone mineral density, and bone turnover markers outlining the literature and guideline support.
  • ||||||||||  Prolia (denosumab) / Amgen
    RISK OF DEVELOPING OSTEOPOROSIS AFTER HELICOBACTER PYLORI ERADICATION; A PROSPECTIVE OBSERVATIONAL COHORT STUDY (Poster Stage 5) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_2944;    
    In this narrative review, we highlighted the effects of denosumab in men with osteoporosis, subsequent changes in bone mineral density, and bone turnover markers outlining the literature and guideline support. The beneficial effect of HP eradication on preventing osteoporosis was observed in this study, even after the adjustment of other confounding factors.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Review, Journal:  Utility of a bone health clinic in bridging the osteoporosis care gap: Prescribing habit review at an academic institution. (Pubmed Central) -  Jul 18, 2024   
    The beneficial effect of HP eradication on preventing osteoporosis was observed in this study, even after the adjustment of other confounding factors. Establishing a bone health clinic dedicated to osteoporosis management leads to significantly higher prescription rates per provider, increased utilization of anabolic therapies compared to other specialties, and more male patients being treated-an often-neglected population in osteoporosis.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Giant cell tumor of femur with single pulmonary metastasis - yet another curative oligometastasis. (Pubmed Central) -  Jul 18, 2024   
    We report a case of GCT with solitary pulmonary metastasis who had significant clinical benefit and disease control with sequential application of surgical resection of pulmonary metastasis, local external beam radiation therapy (EBRT), and systemic Denosumab. We wish to highlight that even in metastatic GCT, there is significant clinical benefit in aggressive treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Giant Cell tumour of bone a progressing danger (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_1975;    
    It usually develops near a joint at the end of the bone. Most occur in the long bones of the legs and arms.Giant cell tumors most often occur in young adults when skeletal bone growth is complete.The exact cause of giant cell tumors remains unknown.Symptoms may include joint pain, swelling, and limited movement.Diagnostic tests may include X-rays, biopsy, and bone scans.The goal for treatment of a giantcell tumor is to remove the tumor and prevent damage to the affected bone.Tumors that can't be removed surgically can often be controlled and sometimes destroyed with radiation therapy.Giant cell tumors can come back.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Journal:  Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients. (Pubmed Central) -  Jul 13, 2024   
    Higher plasma RANKL concentrations were significantly associated with lower depressive symptoms in HD patients.Trial registration WHO registry, No. KCT0003281, date: January 12, 2017.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Preventive Effects of Dental Pulp Stem Cell-conditioned Media on Anti-RANKL Antibody-Related Osteonecrosis of the Jaw. (Pubmed Central) -  Jul 13, 2024   
    Medication-related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with antiresorptive agents (ARAs) such as bisphosphonate (BP) or denosumab, an antibody targeting receptor activator of NF-?B ligand...Further, the expression of Wnt signaling molecules, which had been suppressed, was improved. These findings collectively suggest that DPSC-CM prevents ONJ development in a murine DRONJ model.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  A rare case of giant cell tumor of the anterior rib presenting as a breast mass. (Pubmed Central) -  Jul 10, 2024   
    This case highlights the importance of keeping chest wall lesions in the differential for lesions presenting clinically as breast lesions. Despite the rarity of giant cell tumor of the anterior rib and its unusual presentation as a breast mass, appropriate diagnostic imaging work-up allowed for successful diagnosis and treatment in this case.
  • ||||||||||  Journal:  Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) -  Jul 9, 2024   
    Despite the rarity of giant cell tumor of the anterior rib and its unusual presentation as a breast mass, appropriate diagnostic imaging work-up allowed for successful diagnosis and treatment in this case. No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Efficacy and safety of denosumab de?escalation in giant cell tumor of bone. (Pubmed Central) -  Jul 5, 2024   
    In conclusion, 12-weekly de-escalated denosumab treatment showed clinical benefits as a maintenance treatment in patients with unresectable GCTB, in addition to sustained stable tumor control and improved clinical symptoms with standard treatment. A 24-weekly treatment can also be administered, with careful attention paid to detecting local recurrence.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  BoneZone: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (clinicaltrials.gov) -  Jul 4, 2024   
    P2,  N=450, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: May 2025 --> Feb 2027 | Trial primary completion date: Dec 2023 --> Feb 2027
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Lincoln Sign: A Rare Presentation of Medication-related Osteonecrosis of the Jaw. (Pubmed Central) -  Jul 1, 2024   
    A 52-year-old female patient with metastatic breast cancer receiving denosumab for 7 years presented with marked diffuse tracer uptake in the mandible on Tc-99m-methylene diphosphonate bone scintigraphy, resembling the Lincoln sign...MRONJ, a potential complication of bone-modifying agents, is more prevalent in advanced malignancy cases. The Lincoln sign has not been previously reported in MRONJ, emphasizing its consideration in cancer patients undergoing bone-modifying agent treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal, Metastases:  Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches. (Pubmed Central) -  Jun 27, 2024   
    To the best of our knowledge, there has been no previous review addressing these matters cumulatively, highlighting a significant gap in the existing scholarly literature. By shedding light on the nuances of chondroblastoma metastasis, this review contributes to the advancement of knowledge in this field and informs clinical decision-making for improved patient care.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies. (Pubmed Central) -  Jun 26, 2024   
    Among the known treatment methods, bisphosphonates, calcitonin, steroids, and denosumab should be mentioned, but ongoing research promotes progress in pharmacotherapy. Given the rising global cancer prevalence, the problem of hypercalcemia is of high importance and requires attention.